Daewoong Pharmaceutical has started to attract talent from Indonesia and has hired 19 biopharmaceutical experts from the country to join their workforce in Korea, with the aim of enhancing their global R&D capabilities.

The recruitment process comes after Daewoong selected Indonesia as a hub country in Southeast Asia.

The Korean company is promoting business diversification such as local production, technology transfer, and the establishment of research institutes based on a fully localized strategy to grow into a top local pharmaceutical company.

The company has been recruiting and fostering Indonesian talents with various capabilities to grow together with Indonesia, not just sell products.

According to Daewoong, the 19 Indonesians that arrived in Korea on April 24 are experts in the fields of pharmacy, biology, chemistry, and engineering, and will work quality department at Daewoong's Osong Smart Factory, in Osong, North Chungcheong Province. 

As a company that prioritizes the growth of its employees over the growth of the company, Daewoong also plans to provide them with opportunities to expand their roles as experts in related fields such as production, research, development, and global business through its Career Development Program (CDP), a differentiated career development personnel system.

Employees with excellent research capabilities can develop their careers as R&D professionals in research and development through projects that study prescription, process, and quality testing methods for new chemical drugs, generics, reformulated drugs, biologics, and biosimilars in the laboratory.

To help employees adapt to life in Korea and increase their work immersion, the company will also provide a detailed support program, including housing and financial transaction guidance.

"I am happy to start my first step to grow as a global pharmaceutical industry professional at Daewoong Pharmaceutical, a leading Korean pharmaceutical company," said Muhamad Ulil Absor, who will be working as a member of the QC team at the Osong plant. "Daewoong provides full support in various aspects such as housing, language training, and life guidance so that I can immerse myself in my work, so I will strive to repay it with my best performance."

The company also plans to continue hiring experts from Indonesia and bring them to work at the Korean production facility and has already recruited 60 experts as the second group in February.

Currently, they are undergoing an internship in Indonesia, and those who pass the final evaluation will be assigned to the Korean production facility.

Daewoong Pharmaceutical will also conduct large-scale recruitment activities in the second half of this year to select more global talents in Indonesia.

"We are pleased to work with talented Indonesians, and I think this first round of global talent recruitment is a milestone that shows that Daewoong Pharmaceutical is continuing to grow in global markets, including Indonesia," Daewoong CEO Jeon Seng-ho said. "We plan to continue to expand local laboratories and production facilities in Indonesia to foster talent in the country."

Daewoong has been making great efforts and investments in Indonesia since establishing a subsidiary in Jakarta, the capital of Indonesia, in 2005.

In 2012, the company established Daewoong Infion, a joint venture with local pharmaceutical company PT. Infion and built Indonesia's first biopharmaceutical plant, laying the foundation for direct R&D, production, and sales of biopharmaceuticals in Indonesia.

The joint venture currently manufactures and markets Epodion, which treats anemia in patients with chronic kidney failure and cancer patients undergoing kidney dialysis and is the first biosimilar produced locally in Indonesia.